Menu Close

Trending

Bayer grabs Chinese okay for CKD therapy Kerendia
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
A 3-step guide to addressing difficult issues and creating mutual solutions
AZ takes aim at BMS’ lead in neoadjuvant NSCLC
Blueprint cashes in on the past to build its future

tralokinumab

Human skin macro photo

News/ News/ Sales and Marketing

Leo puts target on Dupixent in US as FDA clears tralokinumab

, , , , , , , , , , , , , 0 Comment

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA

X
Leo puts target on Dupixent in US as FDA clears tralokinumab
https://pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/
Background of the human skin. macro

Market Access/ News/ News

Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EU

, , , , , , , , 0 Comment

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic

X
Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EU
https://pharmaphorum.com/news/eyeing-dupixents-territory-leo-pharma-files-tralokinumab-in-eu/

Login

CONTINUE TO SITE >
X
Close in 10 seconds